Real-World Data Confirm Efficacy of 177Lutetium PSMA-617 for mCRPC
A PSA decrease of 30% or more occurred in 77.8% of patients after the third treatment cycle, investigators reported.
A PSA decrease of 30% or more occurred in 77.8% of patients after the third treatment cycle, investigators reported.
Investigators believe their study is the first to demonstrate the adverse impact of LVI on overall survival in patients with surgically treated renal cell carcinoma.
Adding cabazitaxel to abiraterone acetate and prednisone improves outcomes in patients with metastatic castration-resistant prostate cancer, a phase 2 study suggests.
Investigators reported findings from one of the largest cohorts of patients treated with androgen receptor pathway inhibitors.
In a retrospective study of men on active surveillance for localized prostate cancer, testosterone replacement therapy did not increase the likelihood of converting to treatment.
At ASCO 2023, investigators reported results from phase 3 trials that could improve therapeutic approaches to bladder, prostate, and kidney cancer.
Erdafitinib alone or in combination with cetrelimab has shown activity in a phase 2 trial of patients with FGFR-altered metastatic urothelial carcinoma.
Prostate radiotherapy added to intensified systemic therapy for de novo low-volume mCSPC decreases the risk of radiographic disease progression.
Immune checkpoint inhibitor rechallenge did not improve outcomes in patients with advanced renal cell carcinoma in the phase 3 CONTACT-03 trial.
Erdafitinib improves survival vs chemotherapy in patients with metastatic urothelial carcinoma and select FGFR alterations who were previously treated with immune checkpoint inhibitors, a phase 3 trial suggests.